Skip to main content

Table 4 Bayesian Analysis of Change from Baseline CAT Score up to Month 6

From: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

 

Placebo

DNX 5 mg

DNX 10 mg

DNX 25 mg

DNX 35 mg

DNX 50 mg

N

101

102

100

103

100

99

Baseline CAT Total Score

18.2 (7.72)

18.3 (7.11)

17.8 (6.99)

18.2 (7.80)

19.1 (6.74)

17.5 (6.20)

n

84

94

86

87

85

83

Mean Change from Baseline (90% CI)

−1.39 (−2.29,-0.47)

−1.39 (− 2.27,-0.51)

−1.23 (− 2.13,-0.32)

−0.97 (−1.91,-0.04)

−1.56 (− 2.47,-0.64)

− 1.32 (− 2.24,-0.39)

Mean Difference from Placebo (90% CI)

 

−0.01 (− 1.29,1.29)

0.16 (− 1.12,1.46)

0.41 (− 0.88,1.69)

−0.17 (− 1.48,1.10)

0.07 (− 1.26,1.37)

  1. N Number enrolled, n Number of subjects with analysable data at the current time point; CI Credible interval